Markets
Moderna Stock Soars 9.26% After Raising Sales Outlook — Adding $8.9 Billion In Market Value
The vaccine maker returned to quarterly profit and now expects 2026 revenue growth of 15% to 25%.
MRNA
Moderna (MRNA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Moderna Counts On Its Patient Data To Keep AI Rivals From Catching Up
Melanoma results expand the evidence behind its individualized cancer therapy, but deeper patient analysis still has limits.
SEC Filings
Moderna Posts $162 Million Quarterly Profit And Lifts 2026 Revenue Growth Outlook To 15% To 25%
The mRNA vaccine maker also raised its year-end cash forecast to $8.1 billion to $8.3 billion and trimmed its research budget.
Markets
Moderna Stock Surges 12% On First Day In The Nasdaq-100, Adding Nearly $10 Billion To Reach Highest Level Since 2022
Shares jumped to their highest point since 2022 as Moderna joined the index, extending a nearly 600% run so far this year.